Boniva sNDA For Monthly Dosing Moves Roche/GSK Osteoporosis Drug Closer To Launch
This article was originally published in The Pink Sheet Daily
Executive Summary
Boniva (ibandronate) cleared FDA in May 2003 with a once-daily regimen, but the firms opted to postpone launch of the oral bisphosphonate pending approval of a less frequent dosing regimen. Competing osteoporosis treatments are dosed once-weekly.